All stock lists
Gyre Therapeutics, Inc. (NASDAQ:GYRE)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
4.28-0.37 (-7.97%)
Market cap
$454M
Insider Score
Health Score
Analyst consensus
Listed since
Apr 12, 2006
Website
Insider Score
––Not scored
GYRE Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Fair
From GYRE’s reported statements · Q3 2026 (trailing 12 months)
Profitability0 / 20
Loses money on what it sells.
- Revenue
- $121.8M
- Net income
- -$25.0M
- Net margin
- -20.5%
Leverage20 / 20
Little or no net debt.
- Total debt
- $3.0M
- Cash
- $41.6M
- Debt / equity
- 0.03
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $123.4M
- Current liabilities
- $28.6M
- Current ratio
- 4.32
Cash generation0 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$23.2M
- Free cash flow
- -$24.7M
- FCF margin
- -20.3%
Dilution & runway5 / 20
Heavy dilution — shareholders are paying for the business.
- Shares outstanding
- 106.3M
- Share growth (1y)
- 19.3%
- Cash runway
- 22 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
GYRE Income Statement
| Fiscal Period | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | 32.93 M | 29.11 M | 22.52 M | 37.20 M | 30.56 M | 29.73 M |
| Revenue Growth (YoY) | 7.75 % | -2.12 % | 2.09 % | 33.45 % | 19.92 % | 17.88 % |
| Cost of Revenue | 1.95 M | 2.21 M | 1.23 M | 1.74 M | 1.63 M | 1.15 M |
| Gross Profit | 30.99 M | 26.90 M | 21.29 M | 35.45 M | 28.94 M | 28.58 M |
| SG&A Expense | 23.95 M | 21.62 M | 21.36 M | 30.52 M | 19.65 M | 22.47 M |
| R&D Expense | 8.48 M | 19.14 M | 6.74 M | 4.82 M | 2.36 M | 8.35 M |
| Operating Expenses | 32.51 M | 41.26 M | 30.65 M | 35.33 M | 22.01 M | 30.82 M |
| Operating Income | -1.52 M | -14.36 M | -9.36 M | 120.00 K | 6.92 M | -2.24 M |
| Pretax Income | -1.75 M | -14.43 M | -9.24 M | -66.00 K | 7.63 M | -1.57 M |
| Tax Provision | -733.00 K | -164.00 K | -621.00 K | 1.30 M | 1.69 M | 662.00 K |
| Net Income | -4.05 M | -10.61 M | -8.62 M | -1.72 M | 3.61 M | 598.00 K |
| EPS (Basic) | -0.04 | -0.12 | -0.10 | -0.02 | 0.04 | -0.02 |
| EPS (Diluted) | -0.04 | -0.12 | -0.10 | -0.02 | 0.03 | -0.03 |
| Shares Outstanding | 106.30 M | 100.64 M | 91.32 M | 91.16 M | 89.12 M | 89.12 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.